The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization (CDSCO) for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19
To manufacture and commercialise baricitinib in India, approved for use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults
This medication is usually used to treat rheumatoid arthritis, and was initially identified by the Imperial College London using artificial intelligence as a drug that could have anti-viral and anti-inflammatory effects.
